Log in

Antares Pharma Stock Forecast, Price & News

0.00 (0.00 %)
(As of 09/17/2020 12:00 AM ET)
Today's Range
Now: $2.77
50-Day Range
MA: $2.77
52-Week Range
Now: $2.77
Volume425,167 shs
Average Volume1.32 million shs
Market Capitalization$460.08 million
P/E Ratio69.27
Dividend YieldN/A
Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.
Read More
Antares Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.84 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
Current SymbolNASDAQ:ATRS



Sales & Book Value

Annual Sales$123.86 million
Cash Flow$0.00 per share
Book Value$0.33 per share


Net Income$-2,030,000.00


Market Cap$460.08 million
Next Earnings Date11/3/2020 (Estimated)
0.00 (0.00 %)
(As of 09/17/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

How has Antares Pharma's stock price been impacted by Coronavirus (COVID-19)?

Antares Pharma's stock was trading at $3.00 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ATRS shares have decreased by 7.3% and is now trading at $2.78.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Antares Pharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Antares Pharma

When is Antares Pharma's next earnings date?

Antares Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Antares Pharma

How were Antares Pharma's earnings last quarter?

Antares Pharma Inc (NASDAQ:ATRS) posted its quarterly earnings data on Thursday, August, 6th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.00 by $0.01. The specialty pharmaceutical company earned $32.38 million during the quarter, compared to analyst estimates of $29.25 million. Antares Pharma had a net margin of 4.04% and a return on equity of 10.58%.
View Antares Pharma's earnings history

What guidance has Antares Pharma issued on next quarter's earnings?

Antares Pharma updated its FY 2020 Pre-Market earnings guidance on Thursday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $135-155 million, compared to the consensus revenue estimate of $133.28 million.

What price target have analysts set for ATRS?

4 Wall Street analysts have issued 1 year price targets for Antares Pharma's shares. Their forecasts range from $4.50 to $7.00. On average, they expect Antares Pharma's stock price to reach $5.63 in the next year. This suggests a possible upside of 102.3% from the stock's current price.
View analysts' price targets for Antares Pharma

Are investors shorting Antares Pharma?

Antares Pharma saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 4,330,000 shares, an increase of 13.4% from the April 15th total of 3,820,000 shares. Based on an average daily trading volume, of 1,640,000 shares, the days-to-cover ratio is presently 2.6 days. Approximately 2.8% of the shares of the stock are short sold.
View Antares Pharma's Short Interest

Who are some of Antares Pharma's key competitors?

What other stocks do shareholders of Antares Pharma own?

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the following people:
  • Mr. Robert F. Apple, CEO, Pres & Director (Age 53)
  • Mr. Fred M. Powell, Exec. VP & CFO (Age 58)
  • Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 52)
  • Dr. James Patrick Tursi, EVP, Head of R&D & Chief Medical Officer (Age 54)
  • Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 56)

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

Who are Antares Pharma's major shareholders?

Antares Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.86%), FMR LLC (2.78%), Sargent Investment Group LLC (2.39%), Centric Wealth Management (2.17%), Silvercrest Asset Management Group LLC (1.19%) and Oracle Investment Management Inc. (1.02%). Company insiders that own Antares Pharma stock include Jacques Gonella, Leonard S Jacob, Marvin Samson, Robert F Apple and Thomas J Garrity.
View institutional ownership trends for Antares Pharma

Which major investors are selling Antares Pharma stock?

ATRS stock was sold by a variety of institutional investors in the last quarter, including Sargent Investment Group LLC, Intrinsic Edge Capital Management LLC, Marshall Wace LLP, Marshall Wace North America L.P., UBS Group AG, Private Advisor Group LLC, Engineers Gate Manager LP, and Pinnacle Associates Ltd.. Company insiders that have sold Antares Pharma company stock in the last year include Marvin Samson, Robert F Apple, and Thomas J Garrity.
View insider buying and selling activity for Antares Pharma

Which major investors are buying Antares Pharma stock?

ATRS stock was acquired by a variety of institutional investors in the last quarter, including Centric Wealth Management, FMR LLC, Asymmetry Capital Management L.P., AQR Capital Management LLC, Oracle Investment Management Inc., Assenagon Asset Management S.A., Silvercrest Asset Management Group LLC, and Goldman Sachs Group Inc..
View insider buying and selling activity for Antares Pharma

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $2.78.

How big of a company is Antares Pharma?

Antares Pharma has a market capitalization of $461.74 million and generates $123.86 million in revenue each year. The specialty pharmaceutical company earns $-2,030,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Antares Pharma employs 165 workers across the globe.

What is Antares Pharma's official website?

The official website for Antares Pharma is www.antarespharma.com.

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.